<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38327">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660022</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_12_002</org_study_id>
    <nct_id>NCT01660022</nct_id>
  </id_info>
  <brief_title>Safety Tolerability &amp; Pharmacokinetics of Co-administered Single Doses of OZ439 &amp; Piperaquine to Healthy Subjects</brief_title>
  <official_title>A Phase I Study to Investigate the Safety, Tolerability &amp; Pharmacokinetics of Co-administered Single Doses of OZ439 and Piperaquine to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

        -  To determine the safety and tolerability of co-administered single doses of OZ439 and
           piperaquine

        -  To determine the effect of piperaquine on the plasma exposure and pharmacokinetic
           properties of OZ439 and its metabolites

        -  To determine the pharmacokinetics of piperaquine on co-administration with OZ439
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC 0-inf) extrapolated to infinity</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity (AUC 0-inf)</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>OZ439 single 100mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo to OZ439 single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 single B mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 single C mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 single D mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 100mg &amp; Piperaquine 160mg single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane;  Piperaquine is a bisquinoline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo for  both OZ439 &amp; Piperaquine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 100mg &amp; Piperaquine W mg single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane; Piperaquine is a bisquinoline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 B mg &amp; Piperaquine X mg single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane; Piperaquine is a bisquinoline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 C mg &amp; Piperaquine Y mg single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane; Piperaquine is a bisquinoline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 D mg &amp; Piperaquine Z mg single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 is a novel synthetic trioxolane; Piperaquine is a bisquinoline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mg OZ439 single oral dose</intervention_name>
    <description>100mg OZ439 oral suspension single dose</description>
    <arm_group_label>OZ439 single 100mg dose</arm_group_label>
    <arm_group_label>OZ439 100mg &amp; Piperaquine 160mg single doses</arm_group_label>
    <arm_group_label>OZ439 100mg &amp; Piperaquine W mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to OZ439 single oral dose</intervention_name>
    <description>placebo to OZ439 oral suspension single dose</description>
    <arm_group_label>placebo to OZ439 single dose</arm_group_label>
    <arm_group_label>placebo for  both OZ439 &amp; Piperaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B mg OZ439 single oral dose</intervention_name>
    <description>B mg OZ439 oral suspension single dose.  Doses may be the same as those explored in previous cohorts or may differ, depending on the results of the PK &amp; safety data review</description>
    <arm_group_label>OZ439 single B mg dose</arm_group_label>
    <arm_group_label>OZ439 B mg &amp; Piperaquine X mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>160mg Piperaquine single oral dose</intervention_name>
    <description>160 mg Piperaquine tablet</description>
    <arm_group_label>OZ439 100mg &amp; Piperaquine 160mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>W mg Piperaquine single oral dose</intervention_name>
    <description>W mg Piperaquine (as 160 mg or 320 mg tablets).  Doses may be the same as those explored in previous cohorts or may differ, depending on the results of the PK &amp; safety data review</description>
    <arm_group_label>OZ439 100mg &amp; Piperaquine W mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X mg Piperaquine single oral dose</intervention_name>
    <description>X mg Piperaquine (as 160 mg or 320 mg tablets).  Doses may be the same as those explored in previous cohorts or may differ, depending on the results of the PK &amp; safety data review</description>
    <arm_group_label>OZ439 B mg &amp; Piperaquine X mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y mg Piperaquine single oral dose</intervention_name>
    <description>Y mg Piperaquine (as 160 mg or 320 mg tablets).  Doses may be the same as those explored in previous cohorts or may differ, depending on the results of the PK &amp; safety data review</description>
    <arm_group_label>OZ439 C mg &amp; Piperaquine Y mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z mg Piperaquine single oral dose</intervention_name>
    <description>Z mg Piperaquine (as 160 mg or 320 mg tablets).  Doses may be the same as those explored in previous cohorts or may differ, depending on the results of the PK &amp; safety data review</description>
    <arm_group_label>OZ439 D mg &amp; Piperaquine Z mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C mg OZ439 single oral dose</intervention_name>
    <description>C mg OZ439 oral suspension single dose. Doses may be the same as those explored in previous cohorts or may differ, depending on the results of the PK &amp; safety data review</description>
    <arm_group_label>OZ439 single C mg dose</arm_group_label>
    <arm_group_label>OZ439 C mg &amp; Piperaquine Y mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D mg OZ439 single oral dose</intervention_name>
    <description>D mg OZ439 oral suspension single dose. Doses may be the same as those explored in previous cohorts or may differ, depending on the results of the PK &amp; safety data review</description>
    <arm_group_label>OZ439 single D mg dose</arm_group_label>
    <arm_group_label>OZ439 D mg &amp; Piperaquine Z mg single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to Piperaquine</intervention_name>
    <description>placebo to Piperaquine 320 mg tablet / placebo to Piperaquine 160 mg tablet</description>
    <arm_group_label>placebo for  both OZ439 &amp; Piperaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males &amp; females, 18-55 years old

          -  BMI 18 to 30kg/m2; total body weight &gt;50kg

          -  Healthy, determined by pre-study medical history, physical examination vital signs,
             12 Lead ECG

          -  Females of non-childbearing potential. Surgically sterilized or post-menopausal
             (amenorrhea for at least 2 years confirmed by a serum FSH within the reference range
             for postmenopausal females) may be included

          -  Males must agree to use a double barrier method of contraception including condom
             plus diaphragm/IUD/stable oral/transdermal/injectable hormonal contraceptive by the
             female partner for at least 14 days prior to first dose of study drug through 90 days
             after the last dose of study drug. Abstinent subjects must agree to use a double
             barrier method if they start sexual relationships during the study and for up to 90
             days after the last dose of study drug

          -  Lab tests at screening within the reference ranges or if outside normal range not
             clinically significant. AST, ALT and bilirubin must be within the normal range

          -  Ability to comprehend the full nature and purpose of the study, including possible
             risks and side effects; ability to co-operate with the Investigator and to comply
             with the requirements of the study

          -  Signed written informed consent prior to inclusion

        Exclusion Criteria:

          -  Evidence/history of clinically significant oncology, pulmonary, hepatic,
             cardiovascular, haematology, metabolic, neurological, immunologic, nephrology,
             endocrine, psychiatric disease, or current infection

          -  Evidence or history of clinically significant gastrointestinal (excluding
             appendectomy, herniorrhaphy or cholecystectomy) disease

          -  Any condition that could affect drug absorption, e.g. gastrectomy, diarrhea

          -  Clinically relevant abnormalities in ECG; subjects with QTc greater than 450 msec as
             corrected by the Fridericia's formula are excluded

          -  Family history of sudden death or of congenital prolongation of QTc interval or known
             congenital prolongation of QTc-interval or any clinical condition known to prolong
             the QTc interval

          -  History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia

          -  Electrolyte disturbances, particularly hypokalemia, hypocalcaemia or hypomagnesaemia

          -  History of drug or alcohol abuse within 2 years of Screening

          -  Tobacco users (includes stopping smoking within 90 days of screening  [Tobacco use
             includes smoking and use of snuff/chewing tobacco/other nicotine containing products]

          -  Participation in evaluation of any drug for 3 months before the study

          -  Administration of ANY systemic medication/herbal product within 14 days of first dose
             of study drug. If agreed that the specific product would not interfere with the
             safety of the subject or the objectives of the study, topical treatments/vitamins and
             mineral supplements at recommended daily amounts and not containing other substances
             are allowed until 4 days before dosing. Ibuprofen up to 1200mg per day and
             paracetamol up to 2g per day for no more than 3 consecutive days or 6 non-consecutive
             days are allowed until 24h before dosing with study drug. Longer exclusion periods
             apply for:

               1. amiodarone and hydroxychloroquine (210 days)

               2. monoclonal antibodies/immunoglobulins/other therapeutic proteins and
                  experimental drugs whose half-life is not known to the Investigator (120 days)

               3. experimental drugs whose half-life is known to the Investigator (5 half-lives
                  plus 14 days)

               4. chloroquine, piperaquine and flunarizine (100 days)

               5. fluoxetine (75 days)

               6. benzodiazepines (for midazolam, lorazepam and triazolam the exclusion period is
                  14 days), chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone,
                  phenprocoumon and CYP3A4 inducers not already mentioned including but not
                  restricted to rifampin, carbamazepine, oxcarbazepine, phenytoin and St John's
                  Wort (35 days)

          -  unaccustomed strenuous exercise within 7 days of any study visit

          -  Alcohol consumption within 24 hours of any study visit, or consumption of &gt;5 units
             alcohol in any one day or consumption of &gt;15 units alcohol in any one week throughout
             the study. Alcohol screening will be performed at each admission

          -  Consumption of any fruit juice or food containing grapefruit within 7 days prior to
             the first dose of study drug or throughout the study

          -  Positive test for HIV-1, HBsAg or HCV

          -  Positive urine drug screen at Screening or admission

          -  History of intolerance/hypersensitivity to PQP or any 4 aminoquinoline or ascertained
             or presumptive hypersensitivity to the active principle and/or formulations'
             ingredients; history of anaphylaxis to drugs or allergic reactions in general, which
             may affect the study outcome

          -  Severe allergies/multiple drug allergies

          -  Volunteers who have donated blood or experienced significant blood loss within 90
             days of screening

          -  Hemoglobin below lower limit of the reference range

          -  Clinically relevant abnormal lab values indicative of physical illness

          -  Abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits in
             the 4 weeks before this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milko M Radicioni, MD PhD Clinical Pharmacology</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Research S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Research S.A.</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH 6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
